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Introduction
Endoscopic ultrasound-guided fine-needle aspiration
(EUS-FNA) was introduced in 1991,1 initially used in
gastrointestinal lesions,2–4 and then later extended for
many other indications, including mediastinal lesions.5
EUS-FNA can provide tissue diagnosis in lung cancer
where bronchoscopic biopsy is non-diagnostic.5 It is
useful as a minimally invasive method for staging of
non-small cell lung cancer (NSCLC).6–21 EUS-FNA
can also provide tissue diagnosis of mediastinal mass
of unknown origin.22,23 It is a minimally invasive pro-
cedure for obtaining tissue diagnosis compared with
invasive procedures such as mediastinoscopy and tho-
racotomy. However, very few data have been re-
ported from Eastern countries. We hereby report our
experience of EUS-FNA for lung and mediastinal
lesions (lung cancers, sarcoidosis, neurogenic tumors).
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Background: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) was initially introduced for diagnosing 
gastrointestinal and pancreatic lesions, and later on for lung and mediastinal lesions. It can provide tissue diagnosis of
lung cancer where bronchoscopy is non-diagnostic. It is a minimally invasive method for lymph node (N) and metastasis
(M) staging of non-small cell lung cancer, and is helpful for tissue proof of mediastinal mass with unknown origin. 
Few data on this topic have been reported from Eastern countries. We report our experience of using EUS-FNA for tissue
proof of lung and mediastinal lesions.
Methods: This was a retrospective analysis of prospectively collected data of 20 cases, with 21 EUS-FNAs of lung and
mediastinal lesions (1 EUS-FNA performed on left adrenal gland) for tissue diagnosis and staging. With patients’
informed written consent and fasting for 8 hours, EUS-FNA was performed with a linear echoendoscope using a 22- or
25-gauge needle and a syringe with 10–20 mL negative pressure. The cytology smear was fixed with 98% alcohol, while
cell-block and tissue were sent for histology. There was no onsite cytopathologist. EUS-guided Tru-Cut biopsy was performed
in 1 case. Malignancy was proven by FNA biopsy results, mediastinoscopy when performed, or by clinical course and 
follow-up.
Results: Of the 20 cases, 19 were male and 1 was female; mean age was 63.9 ± 12.6 years. Median tumor size was
2.6 cm (range, 1.8–5.0 cm), and median number of punctures was 3 (range, 2–7). Eighteen EUS-FNA punctures were 
performed at the mediastinum, and 2 directly on lung mass. The size of the left adrenal metastasis for extramediastinal
EUS-FNA was 1.2 cm. Of the 16 EUS-FNA-positive cases, 12 were for tissue diagnosis, 3 were for both tissue diagnosis
and staging (N2 and M1 staging), and 1 was for N2 staging. EUS-FNA provided a tissue diagnosis in 14 cases where
bronchoscopy was negative. In 16 positive EUS-FNAs, all except 1 had adequate tissue for FNA biopsy. The sensitivity,
specificity, and diagnostic accuracy of EUS-FNA were 84.2%, 100%, and 85%, respectively.
Conclusion: EUS-FNA can diagnose lung cancer by confirmation of mediastinal lymph node metastasis, by direct puncture
of lung tumor close to the esophagus. It is useful for lymph node (N) stations 5, 7, 8 and metastasis (M) staging in non-small
cell lung cancer, and for the diagnosis of mediastinal mass of unknown etiology. [J Chin Med Assoc 2010;73(10):523–529]
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Methods
From June 2005 to June 2009, a retrospective analysis
of prospectively collected data of 20 cases of lung and
mediastinal lesions was performed. Twenty patients
with 21 EUS-FNAs of lung and mediastinal lesions
after bronchoscopy and computed tomography (CT)-
guided (Case 18) FNA biopsy were enrolled for tissue
diagnosis and staging of NSCLC, both N staging
(Figure 1) and M staging (Figure 2).
After informed written consent was obtained and
patients had fasted for 8 hours, EUS-FNA was per-
formed with a linear echoendoscope (GF-UCT2000,
EUC2000 unit; Olympus, Tokyo, Japan). The FNA
needle set was fixed at the working channel of the
endoscope. With no intervening vascular structure
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Figure 1. Adenocarcinoma of the right lung,
proven by EUS-FNA of subcarinal lymph node,
enabling a staging of IIIA. Computed tomog-
raphy shows: (A) right lung tumor (arrow);
(B) subcarinal lymph node (N2) metastasis
(arrow). (C) EUS-FNA (arrow). Adenocarci-
noma is shown on: (D) cytology (arrow;
400×); (E) cell block (arrow; 400×).
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Figure 2. Left lung adenocarcinoma with left adrenal gland metastasis, proven by EUS-FNA, enabling a staging of M1. (A) Metastatic left
adrenal gland, 1.2 cm in size (arrow). (B) EUS-FNA of the left adrenal gland (arrow). Adenocarcinoma is shown on: (C) cytology (arrow;
400×); (D, E) EUS-FNA biopsy histology (arrows; 400×).
J Chin Med Assoc • October 2010 • Vol 73 • No 10 525
EUS-FNA in lung and mediastinal lesions
Table 1. Result of endoscopic ultrasound-guided fine-needle aspiration of lung and mediastinal lesions
Case Sex
Age Lesion EUS-FNA Size Punctures FNA FNAB Cell 
Diagnosis
(yr) location site (cm) (n) block
1 M 67 RUL Media station 7 2.6 2 –ve No tissue –ve Squamous cell carcinoma 
of lung, post CCRT
2 M 51 RUL Media station 5 2 3 + ve + ve + ve Small cell carcinoma of lung 
(bronchoscopic cytology 
suspicious)
3 M 74 RML Media station 7 3.8 2 + ve + ve + ve Extensive small cell 
carcinoma of lung
4 M 79 RML Media region 8 4.5 2 + ve + ve + ve Squamous cell 
carcinoma of lung*
5 M 55 Media Media station 8 2.2 3 –ve –ve –ve Sarcoidosis
6 M 58 LUL Media station 8 2.3 3 –ve –ve –ve Adenocarcinoma of lung
7 M 54 LUL Media station 7 2 3 + ve + ve + ve Small cell carcinoma of lung
8 M 55 LLL Media station 8 2 3 + ve + ve + ve Adenocarcinoma of lung*
9 M 69 RLL Media station 7 3.2 2 + ve + ve + ve Small cell carcinoma of lung
10 M 69 RLL Media station 8 2.8 4 + ve + ve + ve Small cell carcinoma of lung
11 M 81 Media Media station 5† 3.5 3 + ve + ve + ve Schwannoma
12 F 76 LLL Media station 7‡ 2 3 + ve + ve + ve Adenocarcinoma of lung,
left adrenal metastasis
13 M 76 RUL RUL tumor 5 5 + ve + ve + ve Giant cell tumor
14 M 49 RUL Media station 7 1.8 4 + ve –ve + ve Adenocarcinoma of lung
15 M 34 RLL RLL tumor 3.7 4 –ve –ve –ve Organized pneumonia
16 M 63 LLL Media station 5 2.4 5 + ve + ve + ve Adenocarcinoma of lung§
17 M 76 LLL Media station 7 2 7 + ve + ve + ve Squamous cell carcinoma 
of lung
18 M 74 RLL Media station 7 2.7 3 + ve + ve + ve Small cell carcinoma of lung
19 M 50 Media Media station 7 2.5 6 + ve + ve + ve Sarcoidosis
20 M 68 LUL Media station 7 3.2 4 + ve + ve + ve Squamous cell carcinoma 
of lung
*For both tissue diagnosis and N2 staging; †second EUS-FNA positive for malignancy; ‡EUS-FNA for M1 staging (left adrenal gland, 1.2 cm in size); §for N2
staging; negative computed tomography-guided FNAB. EUS-FNA=endoscopic ultrasound-guided fine-needle aspiration; FNAB=FNA biopsy; RUL= right upper lung;
Media = mediastinum; CCRT = combined chemoradiation therapy; RML = right middle lobe; LUL = left upper lung; LLL = left lower lung; RLL = right lower lung.
between the lesion and the scope after turning on the
color Doppler, the needle was pushed into the lesion
with a thrust. The stylet was removed, and the needle
was connected with a 10–20-mL syringe using nega-
tive pressure for aspiration. The 22- or 25-gauge needle
(Echotip; Cook Endoscopy, Winston Salem, NC, USA)
was moved back and forth for 10–20 seconds, with-
drawn into the catheter, and then the whole needle set
was removed from the endoscope. The aspirated mate-
rial was obtained by pushing the stylet into the nee-
dle, and the tissue was sent for cytology and histology.
The cytology smear was fixed with 98% alcohol.
EUS-guided Tru-Cut biopsy with a 19-gauge Quick
Core needle (Cook Endoscopy) was performed in
addition to EUS-FNA (Case 19). There was no onsite
cytopathologist. The sites of EUS-FNA are listed in
Table 1. All EUS-FNA procedures were done from
the esophagus (posterior mediastinum), where the
locations of the lymph nodes are stations 5, 7 and 8,
and direct lung puncture of EUS-FNA were also under-
taken from the esophagus, where the lesions were close
to the esophagus.
Pathology and malignancy were proven by FNA
biopsy results, mediastinoscopy when performed, or by
clinical outcome and follow-up for more than 6 months.
Mediastinal lymph node location was classified accord-
ing to the American Thoracic Society system.24 N2 is
the ipsilateral mediastinal lymph node metastasis, and
N3 is the contralateral mediastinal lymph node metas-
tasis. Station 5 is the aortopulmonary window, station 7
the subcarinal region, and station 8 the paraesophageal
region below the subcarina.
Results
Table 1 shows the results of EUS-FNA for the lung
and mediastinal lesions. There were 20 cases (19 males;
1 female); mean age was 63.9 ± 12.6 years. Median
lung and mediastinum tumor size was 2.6 cm (range,
1.8–5.0 cm), and median number of punctures was 3
(range, 2–7).
There were 21 EUS-FNA punctures in the 20
cases: 18 EUS-FNA punctures (3 cases at station 5, 10
cases at station 7, and 5 cases at station 8) were per-
formed at the mediastinum; 2 were performed directly
on lung masses (Cases 13 and 15, Figure 3); and 1 was
performed for metastasis (M) in the left adrenal gland.
A second EUS-FNA was done in 1 patient (Case 11)
with a negative initial result. The final diagnoses of the
cases were: 6 small cell carcinoma of the lung, 5 ade-
nocarcinoma of the lung, 4 squamous cell carcinoma
of the lung, 1 giant cell carcinoma (poorly differenti-
ated carcinoma) of the lung, 2 sarcoidosis (Figure 4),
1 schwannoma, and 1 organized pneumonia.
Of the 16 EUS-FNA-positive cases (including the
second EUS-FNA in Case 11), 12 were for diagnosis,
3 were for both diagnosis and staging (N2 lymph node
staging and M1 staging for left adrenal gland metasta-
sis), and 1 was for N2 lymph node staging. In the 16
EUS-FNA cases positive for malignancy, 1 had a positive
bronchoscopic biopsy result (Case 16), and another
had pleural effusion cytology suspicious for small cell
carcinoma (Case 2), and EUS-FNA was able to diag-
nose the remaining 14 cases of tumors, making a tissue
diagnosis of 87.5% (14/16 cases). In the 16 EUS-
FNA punctures, all had adequate tissue for FNA biopsy
except for Case 14. Twelve cases had immunohisto-
chemical staining done (including 1 with Tru-Cut
biopsy). Four cases were EUS-FNA-negative for malig-
nancy: 1 true negative (organized pneumonia), and 3
false negatives (1 sarcoidosis, 1 lung cancer, and 1 lung
cancer post chemoradiation therapy).
The sensitivity, specificity, and diagnostic accuracy
of mediastinum and lung EUS-FNA were 84.2%,
100%, and 85%, respectively. Excluding EUS-FNA per-
formed directly on lung masses (right upper lung and
right lower lung), the median mediastinal tumor size was
2.5 cm (range, 1.8–4.5 cm), and the median number
of mediastinal mass punctures was 3 (range, 2–7), with
a sensitivity, specificity, and diagnostic accuracy of 83.3%,
100%, and 83.3%, respectively.
In the EUS-FNA-negative cases, Case 1 was a
documented case of squamous cell carcinoma by
bronchoscopy before combined chemoradiation ther-
apy, who was shown to have residual tumor by fol-
low-up after negative EUS-FNA. Sarcoidosis was
diagnosed by mediastinoscopy in Case 5, by surgery
in Case 6, and by clinical course in Case 15. Case 12
was the patient who had EUS-FNA done in 2
regions, 1 in region 7 and the other in the left adrenal
gland; both EUS-FNAs were positive for malignancy.
There were no complications in our series.
Discussion
Treatment strategies for lung cancers are dependent
on histology (small cell vs. non-small cell) and the
presence of mediastinal or distant spread of the tumor.
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Figure 3. Right lung tumor close to the esophagus, proven by EUS-FNA to be giant cell carcinoma. Right lung tumor is seen on: (A) chest
X-ray (arrow); (B) computed tomography (arrow). (C) EUS-FNA directly on the lung tumor (arrow). (D) Cytology reveals malignant cells
(arrow; 400×). (E, F) Giant cell carcinoma is diagnosed by EUS-FNA biopsy histology (arrows).
A classification for lung cancer staging has been de-
scribed by the American Joint Committee on Cancer24
for NSCLC. Metastases to ipsilateral and subcarinal
nodes (N2) is classified as stage IIIA disease, the man-
agement of which is controversial (presurgical che-
motherapy followed by surgery), whereas treatment
of stage IIIB (metastasis to contralateral mediastinal
nodes, N3) is usually chemoradiation without surgery.
EUS-FNA can obtain a tissue diagnosis in suspected
NSCLC with mediastinal lymph node seen on CT
when transbronchial biopsy is non-diagnostic.5,7,23
In our series, EUS-FNA obtained a tissue diagnosis 
in 14 of 16 cases where bronchoscopic results were
non-diagnostic.
CT is a noninvasive and widely used staging
method for mediastinal lymph node in NSCLC, with
a sensitivity and specificity of 70%.25–27 Positron emis-
sion tomography with fluorodeoxyglucose has an
accuracy of 85% and is noninvasive as well, but gives
false-negative results in lymph nodes with low meta-
bolic activity or when the size is < 1 cm. Positron emis-
sion tomography can also give false-positive results
when lymph nodes have high metabolic activity, such
as in cases of pneumonia and granulomatous diseases.28
Bronchoscopy and transbronchial biopsy has a sensitiv-
ity of 53–70%, but it is not accessible to aortopulmonary
window lymph nodes (station 5) and the inferior
mediastinal region (station 8).29 Mediastinoscopy and
thoracoscopy are invasive, costly, and require general
anesthesia. Mediastinoscopy cannot access lymph
nodes in stations 5 and 8, and had a higher morbidity
of 16% and 1 mortality.30 In contrast, EUS-FNA is
safe and effective, and can easily approach lymph
nodes in stations 5, 7 and 8.10 In our series, the most
common stations of mediastinal lymph nodes that
underwent EUS-FNA, in order of frequency, were
stations 7, 8, and then 5 (Table 1). In our 16 positive
EUS-FNA cases (including the second EUS-FNA in
Case 11), 12 were for diagnosis, 3 were for both diag-
nosis and staging (2 cases of N2 lymph node estab-
lishing a stage of IIIA in Cases 4 and 8, and 1 M1
staging in the left adrenal gland metastasis in Case
12), and 1 was for N2 lymph node staging in Case
16. The smallest size of positive EUS-FNA was the
left adrenal gland metastasis, which was 1.2 cm in
size. In a meta-analysis of 18 studies of EUS-FNA
staging of mediastinal lymph nodes in NSCLC, the
pooled sensitivity and specificity were 83% and 97%,
respectively, with a minor complication rate of only
0.8%.21 In our series, the sensitivity and specificity of
EUS-FNA of mediastinal lymph nodes were 83.3%
and 100%, respectively (excluding 2 cases of direct
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Figure 4. Sarcoidosis diagnosed by EUS-FNA. (A) Chest X-ray shows enlarged hilar lymph node (arrow). (B) Computed tomography
shows enlarged mediastinal lymph nodes (arrows). (C) EUS-FNA of mediastinal lymph node, station 7 (arrow). Non-caseating granuloma
is shown on: (D) cytology (arrow; 400×); (E) EUS-FNA biopsy (arrow; 400×).
lung punctures), with no complications. EUS-FNA
can also detect malignant mediastinal lymph nodes in
CT-negative patients, ranging from 22% to 44%.10,31
EUS-FNA can obtain a tissue diagnosis by directly
puncturing the lung tumor close to the esophagus;25,32
we had 2 cases in which EUS-FNA was performed
directly through the lung mass from the esophagus,
which presented as right upper and right lower lung
masses located close to the esophagus. CT-guided lung
tumor biopsy is invasive and can be complicated by
pneumothorax and hemoptysis.33 A case of transaortic
EUS-FNA of lung tumor using a 25-gauge needle
without complications has been reported.34
Wallace et al reported a complete mediastinoscopy by
combining EUS-FNA and endobronchial ultrasound-
guided FNA (EBUS-FNA), which could achieve 93%
sensitivity in staging mediastinal lymph nodes, instead
of 69% sensitivity for each procedure alone.35
EUS-FNA is also useful for diagnosis in mediasti-
nal lymph nodes of unknown etiology.22 We had a
case of sarcoidosis (Case 19) that was diagnosed by
EUS-FNA; in that case, we also performed EUS-
guided Tru-Cut biopsy, which could be helpful in
cases missed by EUS-FNA.36
Not being a prospective study and the relatively
small number of cases in this series are the study’s
limitations.
In conclusion, EUS-FNA, a minimally invasive
endoscopic procedure, is safe and effective for tis-
sue diagnosis when bronchoscopic results are non-
diagnostic, for mediastinal lymph node (N) and
metastasis (M) staging in NSCLC, and for diagnosis
in mediastinal lymph nodes with unknown etiology.
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